CHMP recommends EU marketing authorisation for Rasonque in metastatic pancreatic cancer
RVMD•The EMA’s CHMP recommended granting Rasonque (daraxonrasib) marketing authorisation in the European Union for metastatic pancreatic cancer.
1. EU authorisation recommendation
The EMA’s CHMP recommended granting Rasonque (daraxonrasib) marketing authorisation in the European Union for metastatic pancreatic cancer.
